Form 4: Replimune CAO Receives Significant Equity Grants

Replimune Group's Chief Accounting Officer, Andrew Schwendenman, has been granted 36,667 restricted stock units and 55,000 stock options as part of a long-term incentive plan.

Summary

• Andrew Schwendenman, Chief Accounting Officer of Replimune Group, Inc., was awarded 36,667 Restricted Stock Units (RSUs) on April 1, 2026.
• Each RSU represents a contingent right to receive one share of common stock, with vesting occurring between 2027 and 2030.
• Schwendenman also received 55,000 employee stock options with an exercise price of $7.61 per share.
• The stock options have a 10-year term, expiring on April 1, 2036, and follow a four-year vesting schedule.
• Following these transactions, the reporting person directly owns 114,951 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event; while the grants show executive commitment, the administrative filing delay is a minor negative for corporate governance optics.

Positives

• Strong alignment of management interests with shareholders through long-term vesting schedules extending to 2030.
• The CAO maintains a significant direct ownership stake of 114,951 shares, indicating confidence in the company's trajectory.
• Equity-based compensation preserves cash for the company's clinical development programs.

Negatives

• The filing was submitted late due to an administrative error, which may indicate minor lapses in internal reporting controls.
• Potential for future share dilution as RSUs vest and options are exercised.

Risks

• The value of the 55,000 stock options is dependent on the share price exceeding the $7.61 exercise price.
• Vesting is subject to continuous service, posing a retention risk if executive turnover occurs before 2030.

Future Outlook

The grants are structured to incentivize long-term performance, with full vesting of the RSUs not occurring until May 2030 and options vesting monthly through April 2030.

Management Comments

• The filing was delayed due to an inadvertent administrative error.

Industry Context

StockSavvy.ai notes that in the high-growth biotechnology sector, equity-heavy compensation for key accounting and administrative officers is standard practice to align internal controls and financial reporting stability with long-term clinical milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with industry standards for mid-cap biotech companies like Amicus Therapeutics or Ultragenyx.
• The use of a 10-year option term is a standard incentive duration for U.S. listed life sciences companies.
• The grant size is proportional to CAO roles in companies with similar market capitalizations in the NASDAQ Biotechnology Index.

Related Party Transactions

• The issuance of equity awards to the Chief Accounting Officer constitutes a standard related-party compensation transaction.

Stakeholder Impact

• Shareholders face a minor dilutive impact of approximately 91,667 shares over the next four years.
• The CAO is further incentivized to maintain rigorous financial oversight through 2030.

Next Steps

• Monitor for similar grants to other C-suite executives which may signal a broader annual compensation cycle.
• Track the stock price relative to the $7.61 strike price to gauge the CAO's unrealized incentive value.

Key Dates

Recommendation

This is a routine executive compensation filing. While it shows management alignment, it does not provide new material information regarding the company's clinical pipeline or financial health that would warrant a change in investment thesis.

Keywords

Replimune Group, REPL, Insider Trading, Executive Compensation, Stock Options, Restricted Stock Units, Andrew Schwendenman, Biotechnology